ARTICLE | Product Development
Cell therapy derived from hypoimmune platform leads to responses without serious side effects, driving up company’s value
By Paul Bonanos, Director of Biopharma Intelligence
January 11, 2024 9:25 PM UTC
Shares of cell therapy company Sana ticked up this week after the company presented early clinical evidence of efficacy for its hypoimmune, allogeneic CAR T therapy in blood cancer patients. But despite some encouraging antitumor efficacy, the results don’t yet show proof that the therapies produce durable responses to validate the company’s thesis.
Sana Biotechnology Inc. (NASDAQ:SANA) is hoping to show that its hypoimmune platform can help overcome rejection of allogeneic cell therapies, giving them a durability advantage. The company has four clinical programs across seven indications in cancer, autoimmune disorders and diabetes…